RESULTS Life expectancy of patients treated by the 1 st treatment option is 32,4 month, and 19,5 month for the 2 nd (see figure 2). Overall costs are €77 289 and €34 806 per patient respectively. ICER for the 1 st option with abiraterone is €2,878 per month. Still it is less than for the drugs, already included in regional governmental reimbursement programs (see table 1). CONCLUSIONS Inclusion of abiraterone into reimbursement programs is in line with current regional healthcare policies. INTRODUCTION Abiraterone is the oral drug indicated for treatment of patients with metastatic castrate-resistant prostate cancer (MCRPC). COU-AA-301 and COU-AA-302 RCTs showed higher overall and progression-free survival for combination of abiraterone and prednisone both before and after the first line of chemotherapy compared to prednisone alone. However, wide use of abiraterone is restrained in Russia due to its high cost. OBJECTIVES The aim of the study is the pharmacoeconomic evaluation of abiraterone used before chemotherapy in patients with MCRPC from Russian healthcare system perspective. METHODS Using Markov model we estimated median overall survival and costs for two therapy options: consecutive use of abiraterone, docetaxel and cabazitaxel (see figure 1) and consecutive use of docetaxel and cabazitaxel (all regimes include prednisolone). Costs related to these options include medication, adverse events treatment, treatment of bone metastases, premedication, pain relief and visits to oncologist. Incremental cost-effectiveness ratio (ICER) was calculated for the 1 st treatment option vs the second one and compared with ICER for antineoplastic drugs that are already included in regional governments reimbursement programs (i.e. bevacizumab, trastuzumab, cetuximab and erlotinib). PHARMACOECONOMIC ANALYSIS OF USING ABIRATERONE FOR TREATMENT OF PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER Avxentyev N. A. 1, 2 , Derkach E. V. 2, 3 1 Research Institute of Finance, Ministry of Finance of the Russian Federation, Moscow 2 Russian Presidential Academy of National Economy and Public Administration, Moscow 3 National center for health technology assessment, Moscow PCN 125 ISPOR 19th Annual European Congress, Vienna, Austria, 29 October-2 November 2016 Notes: Circles denote possible stages: 1 – Abiraterone + prednisolone, 2 – Time to chemotherapy, 3 – Docetaxel + prednisolone, 4 – Time to 2 nd line chemotherapy, 5 – Cabazitaxel + prednisolone, 6 – Tumor progression after cabazitaxel, 7 – palliative care Figure 1. Markov model structure Figure 2. Median overall survival Table 1. ICER for abiraterone and some other antineoplastic drugs Disease, therapy line Therapy Comparison therapy Δ Overall survival ICER MCRPC Abiraterone → docetaxel → cabazitaxel Docetaxel → cabazitaxel 12,9 € 2 878 Metastatic colorectal cancer, 1 st line Bevacizumab + XELOX XELOX 2,3 € 5 377 Metastatic stomach cancer Trastuzumab + capecitabine + cisplatin + fluorouracil Capecitabine + cisplatin + fluorouracil 2,7 € 3 771 Metastatic colorectal cancer, 2 st line Cetuximab + FOLFIRI FOLFIRI 0,7 € 25 222 Metastatic non-small-cell lung cancer, 1 st line Erlotinib Gemcitabine + cisplatin 0,8 € 18 143